PCOS Renamed Ovarian Metabolic Polyendocrine Syndrome

Why this is here: The condition, now known as polyendocrine ovarian metabolic syndrome, is linked to elevated testosterone levels, which contribute to excess hair growth in around 70% of affected women.

At the European Congress of Endocrinology in Prague, Poland, Professor Helena Teede of Monash Health in Australia led the official renaming of polycystic ovary syndrome to polyendocrine ovarian metabolic syndrome. The change, published in The Lancet, aims to better reflect the condition’s complexity and reduce diagnostic delays.

Until now, the term “polycystic” incorrectly suggested an abundance of ovarian cysts. Research since the 1930s shows these are actually immature follicles blocked from fully developing, likely due to excess anti-Müllerian hormone. The condition affects roughly one in ten women and represents the leading cause of female infertility.

The new name acknowledges that the syndrome involves hormonal disruption impacting both ovarian function and metabolism. Elevated androgen levels can cause symptoms like excess hair growth in about 70% of affected women, acne, and increased risk of metabolic diseases. Teede notes ongoing gaps in awareness and care for those with the condition.